A super-oxygenated fluid selected from water, an aqueous solution and a gel is introduced to a living organism via any one of the following routes: transcutaneous, intradermal, subcutaneous, intraperitoneal and oral.

The present invention relates to regentide-034 and, more specifically, to a use of regentide-034 for improving the condition of the skin. Regentide-034 according to the present invention is noncytotoxic and has remarkable effects of skin aging alleviation, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction and skin wound regeneration, and thus can be variously used in the fields of pharmacology, medicine, cosmetics, and food.

The present invention relates to regentide-034 and, more specifically, to a use of regentide-034 for improving the condition of the skin. Regentide-034 according to the present invention is noncytotoxic and has remarkable effects of skin aging alleviation, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction and skin wound regeneration, and thus can be variously used in the fields of pharmacology, medicine, cosmetics, and food.

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.